Genmab at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Genmab exhibits at Booth 3229 at ASH 2026 in New Orleans. Its presence centres on bispecific antibodies in lymphoma, supporting symposia on best practice across non-Hodgkin lymphoma. It also supports symposia on using these antibodies across follicular and diffuse large B-cell lymphoma care, including new standards and future directions.
| Organization | ASH 2026 Attendance |
|---|---|
Genmab Copenhagen, Denmark | |
Danish antibody company developing bispecific antibodies and antibody-drug conjugates, including epcoritamab for lymphoma. | Booth Exhibiting at Booth 3229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. |
Instantly find 20 buyers from Genmab
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction